Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease

Razia, Deepika; Olson, Merle S.; Grief, Katherine; Walia, Rajat; Bremner, Ross M.; Smith, Michael A.; Tokman, Sofya

doi:10.1016/j.healun.2022.09.002

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our COVID-19 ARDS survival post-LT is consistent with other reports. The increased hospital length of stay after transplant is also consistent with other centers' reports of higher morbidity in patient transplanted for this indication [15,16].…”

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

“…Long-term outcomes after LT for COVID-19 related lung disease remains unknown with only a few centers across the United of States of America reporting on their outcomes [15,16]. When compared to hospitalized patients transplanted for restrictive lung disease, Razia et al described 11 patients with COVID-19 ARDS with comparable 1-year survival rate post-LT of approximately 90% [15]. Another study queried the Organ Procurement and Transplant Network database and described similar outcomes and 6-month survival in 227 patients transplanted for COVID-19 related lung disease when compared to 454 matched controls.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Lung Transplantation for COVID-19 Related Lung Disease: A Follow-Up Study of Outcomes from a Medium-Size Lung Transplant Programd

Franco-Palacios¹,

Allenspach²,

Stagner³

et al. 2023

OBM Transplant

View full text Add to dashboard Cite

In the United States of America, COVID-19 acute respiratory distress syndrome (ARDS) and post-COVID pulmonary fibrosis (PCPF) are raising indications for lung transplant (LT). Another indication for LT is underlying fibrosis with SARS-CoV-2 induced interstitial lung disease exacerbation or rapid progressing fibrosis. Only a few centers have reported on their long-term outcomes after LT for COVID-19. Single center retrospective chart review of patients transplanted for COVID-19 related lung disease. The Henry Ford Health System Institutional Board Review Board approved this study as minimal-risk research using data collected for routine clinical practice (#14953).<em> </em>During the study period from January 2021 to June 2023, 12 patients underwent bilateral LT for COVID-19 related lung disease: 6 for COVID-19 ARDS, 4 with worsening of idiopathic pulmonary fibrosis (IPF) and 2 for PCPF. Median survival after LT in months are 18.5 (IQR 12.9, 26) for ARDS; 20.5 (IQR 13.1, 26) for IPF; and 12.6 months for PCPF. Hospital discharge survival was 83% for ARDS and 100% for the fibrotic types of lung disease. The 30-day and 3-month survival was 100% and 91%, respectively, for all COVID-19 related lung diseases. At the time of data collection, 3 patients in this cohort died (2 in the ARDS group). Eight patients were alive over 1-year post-transplant (4 ARDS, 3 patients with IPF prior to COVID-19 and 1 patient with PCPF). LT for COVID-19 related lung disease is associated with several challenges from patient selection to perioperative management. Short- and long-term survival is promising but associated with significant morbidity.

show abstract

Section: Discussionsupporting

confidence: 89%